Eliminating contamination risks and creating safer medicines with animal origin free (AOF) proteins.
Currently Operating in 30 Regions
Press Mentions
July 29, 2021
Laurus Labs Q1FY22 Net Profit Surges 40% To Rs 241 Crore, Led By Anti-HIV Formulation Sales
The earnings before interest, tax, depreciation and ammortisation (EBITDA) margins expanded 210 basis points YoY to 31.3 percent; however, on sequential basis (QoQ), Laurus' EBITDA margins were...
Read on Moneycontrol »November 29, 2020
Laurus Labs gains 7% in two days on acquisition of Richcore Lifesciences
Motilal Oswal Securities maintains 'buy' rating on Laurus Labs with target price of Rs 410 per share
Read on bsindia »November 25, 2020
Hyderabad-based Laurus Labs acquires a majority stake in Richcore Lifesciences
Laurus Labs announced it has signed a definitive agreement to acquire 72.55% of Richcore’s shares from Eight Roads Ventures and VenturEast. This acquisition marks Laurus Labs’ entry into the...
Read on hrnxt.com »July 21, 2020
Biotech company Richcore LifeSciences launches second recombinant protein manufacturing facility in Tumkur
Richore LifeSciences claims that the new facility will include 180 thousand Litre fermentation capability to produce multiple recombinant biotech products
Read on YourStory.com »May 27, 2020
C-CAMP on Twitter
National Biomedical Resources Indigenisation Consortium #NBRIC is delighted to share Bangalore-based @RichcoreIndia has optimised & produced two key enzymes needed for #COVID19 RT-PCR test...
Read on Twitter »More Ventures in Health
Get the Unreasonable Newsletter
Get monthly updates on Laurus Bio (formerly Richcore India) and over 398 other ventures working to solve the world's toughest problems.